Clinical Trials Directory

Trials / Unknown

UnknownNCT02579564

Systemic Chemotherapy Combined With Recombinant Human Adenovirus Type 5 and Endostatin Injections for Treatment Malignant Hydrothorax in NSCLC Patients

Systemic Chemotherapy Combined With Thoracic Cavity Perfusion of Recombinant Human Adenovirus Type 5 and Endostatin Injections Versus Cisplatin for Treatment Malignant Hydrothorax in Non Small Cell Lung Cancer (NSCLC) Patients: A Multi-center, Randomized, Controlled Clinical Trial

Status
Unknown
Phase
Phase 3
Study type
Interventional
Enrollment
134 (estimated)
Sponsor
Xinqiao Hospital of Chongqing · Academic / Other
Sex
All
Age
18 Years – 75 Years
Healthy volunteers
Not accepted

Summary

The purpose of this multi-center clinical trial is to verify more effective on local control of malignant pleural effusions in NSCLC patients by thoracic cavity perfusion of recombinant human adenovirus type 5 injection and recombinant human Endostatin injection (Endostar) compared with cisplatin perfusion, with acceptable side effects.

Detailed description

Malignant pleural effusion, which can malfunction of circulatory and respiratory systems, is a common complication in advanced NSCLC, finally decreases the quality of life and lifespan. Nowadays, it is still a challenge to effectively control malignant pleural effusion. In this multi-center randomized and controlled clinical trial, 134 NSCLC patients diagnosed as malignant pleural effusion in the first time will enroll. Based on systemic chemotherapy and pleural cavity perfusion, all eligible patients are randomly assigned into treatment group (recombinant human adenovirus type 5 and Endostatin injections) and control group (cisplatin) with ratio 1:1. Local control rate and side effects are record respectively. The anticipation is that treatment group obtains faster and longer control of pleural effusion.

Conditions

Interventions

TypeNameDescription
DRUGGemcitabine
DRUGVinorelbine
DRUGPaclitaxel
DRUGPemetrexed
DRUGOncorine
DRUGEndostar
DRUGCisplatin

Timeline

Start date
2016-10-01
Primary completion
2018-06-01
Completion
2018-12-01
First posted
2015-10-19
Last updated
2016-10-21

Source: ClinicalTrials.gov record NCT02579564. Inclusion in this directory is not an endorsement.